Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

The phase II Study is to explore the efficacy and safety of Tislelizumab as consolidation therapy in patients with locally advanced non-small cell lung cancer who have not progressed following neoadjuvant chemotherapy plus Tislelizumab ± Bevacizumab and definitive concurrent chemoradiation therapy.

Trial Details

NCT ID
NCT05468242
Phase
PHASE2
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Neoadjuvant chemo-immunotherapy
  • Bevacizumab
  • Radiotherapy
  • Tislelizumab
Locations (sample)
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • For inclusion in neoadjuvant therapy, patients should fulfil the following criteria:
  • Provision of signed, written and dated informed consent prior to any study specific procedures;
  • Male or female aged 18\~75 years old;
  • Patients must have histologically- or cytologically-documented NSCLC who present with locally advanced (Stage III) disease;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →